Fly News Breaks for December 30, 2019
Dec 30, 2019 | 08:08 EDT
Piper Jaffray analyst David Amsellem said he continues to have a high degree of confidence in Bausch Health's longer-term EBITDA durability as well as its potential for meaningful growth and he thinks it is reasonable to expect further multiple expansion given that Xifaxan and Trulance give it "a growing and durable" gastroenterology franchise and its Dermatology segment is positioned for meaningful growth now that it has finally hit a trough. While he admits that Bausch is still "highly levered," Amsellem does not view the capital structure as "problematic" or a barrier to further value creation, he tells investors. He keeps an Overweight rating on Bausch shares and increased his price target on the stock to $39 from $30.
News For BHC From the Last 2 Days
Nov 24, 2020 | 07:12 EST
Bausch Health Companies and Bausch + Lomb, its leading global eye health business, announced that the Company has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03, or perfluorohexyloctane, as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry Eye Disease, or DED, associated with Meibomian gland dysfunction, or MGD. Enrollment of the first Phase 3 study is currently underway and has reached 85% of its enrollment goal. NOV03 is an investigational, proprietary, water-free and preservative-free solution, based on patented EyeSol technology from Novaliq GmbH1. DED is a chronic and serious disease of the ocular surface.